» Articles » PMID: 789085

Clinical Pharmacokinetics of Pancuronium Bromide

Overview
Specialty Pharmacology
Date 1976 Sep 30
PMID 789085
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Plasma concentrations of pancuronium bromide have been studied in seven surgical patients following a 6 mg intravenous bolus injection of the drug for neuromuscular blockade. Concurrently, evoked muscle twitch response was monitored for each patient as a measure of the pharmacodynamic effect of the drug. The plasma decay curve for pancuronium was found to be biphasic and after rigorous statistical analysis the data were interpreted according to a 2-compartment open model. The half-life of the beta-phase varied between 89.5 and 161.5 min. The apparent volume of distribution of the central compartment ranged from 62.9 to145.5 ml/kg and the plasma clearance from 57.6 to 187.3 ml/min. At the first sign of recovery from neuro-muscular blockade the mean pancuronium plasma level was found to be 0.218 mcg/ml. The mean duration of action as measured from time of onset of paralysis to 20% recovery was 83.4 min with the plasma level at 20% being 0.169 mcg/ml corresponding to 45.4% of dose remaining to be eliminated from the body.

Citing Articles

Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?.

Beaufort T, Proost J, Kuizenga K, Houwertjes M, Kleef U, Wierda J J Pharmacokinet Biopharm. 1999; 27(2):173-90.

PMID: 10567954 DOI: 10.1023/a:1020653922866.


Anaesthesia in the elderly. Special considerations.

Jones A, Hunter J Drugs Aging. 1996; 9(5):319-31.

PMID: 8922559 DOI: 10.2165/00002512-199609050-00003.


Clinical pharmacokinetics of alcuronium chloride in man.

Walker J, SHANKS C, Triggs E Eur J Clin Pharmacol. 1980; 17(6):449-57.

PMID: 7398736 DOI: 10.1007/BF00570163.


Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Ramzan M, Somogyi A, Walker J, SHANKS C, Triggs E Clin Pharmacokinet. 1981; 6(1):25-60.

PMID: 7018787 DOI: 10.2165/00003088-198106010-00002.


An analytical pharmacodynamic model for nondepolarizing neuromuscular blocking agents.

Dhollander A, Delcroix C J Pharmacokinet Biopharm. 1981; 9(1):27-40.

PMID: 6453216 DOI: 10.1007/BF01059341.


References
1.
Agoston S, Vermeer G, Kertsten U, Meijer D . The fate of pancuronium bromide in man. Acta Anaesthesiol Scand. 1973; 17(4):267-75. DOI: 10.1111/j.1399-6576.1973.tb00839.x. View

2.
Katz R . COMPARISON OF ELECTRICAL AND MECHANICAL RECORDING OF SPONTANEOUS AND EVOKED MUSCLE ACTIVITY. THE CLINICAL VALUE OF CONTINUOUS RECORDING AS AN AID TO THE RATIONAL USE OF MUSCLE RELAXANTS DURING ANESTHESIA. Anesthesiology. 1965; 26:204-11. DOI: 10.1097/00000542-196503000-00012. View

3.
McLeod K, Watson M, Rawlins M . Proceedings: Plasma concentrations of pancuronium bromide (pavulon) in patients with normal and impaired renal function. Br J Anaesth. 1975; 47(8):902-3. View

4.
Gibaldi M, Levy G, Hayton W . Kinetics of the elimination and neuromuscular blocking effect of d-tubocurarine in man. Anesthesiology. 1972; 36(3):213-8. DOI: 10.1097/00000542-197203000-00005. View

5.
Fell P, Stevens M . Pharmacokinetics--uses and abuses. Eur J Clin Pharmacol. 1975; 8(3-4):241-8. DOI: 10.1007/BF00567122. View